Rx Industry Post-M&A Integration, Part I
The long-term market cap of big pharma relies heavily on R&D pipeline valuation. But, in the wake of recent merger activity, most pharma companies have focused on producing short-term cost reductions in order to impress the financial markets. There is a way to reconcile these two, preserving the best of long-term R&D assets while cutting costs in other areas.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.